PEHALOVÁ, Lucie, Denisa KREJČÍ, Jana HALÁMKOVÁ, Lenka ŠMARDOVÁ, Lenka ŠNAJDROVÁ a Ladislav DUŠEK. Significant current epidemiological trend: Haematological malignancies as subsequent primary tumours in cancer patients. Cancer Epidemiology. Oxford: Elsevier, 2021, roč. 72, June 2021, s. 1-8. ISSN 1877-7821. Dostupné z: https://dx.doi.org/10.1016/j.canep.2021.101929.
Další formáty:   BibTeX LaTeX RIS
Základní údaje
Originální název Significant current epidemiological trend: Haematological malignancies as subsequent primary tumours in cancer patients
Autoři PEHALOVÁ, Lucie (203 Česká republika, garant, domácí), Denisa KREJČÍ (203 Česká republika, domácí), Jana HALÁMKOVÁ (203 Česká republika, domácí), Lenka ŠMARDOVÁ (203 Česká republika, domácí), Lenka ŠNAJDROVÁ (203 Česká republika, domácí) a Ladislav DUŠEK (203 Česká republika, domácí).
Vydání Cancer Epidemiology, Oxford, Elsevier, 2021, 1877-7821.
Další údaje
Originální jazyk angličtina
Typ výsledku Článek v odborném periodiku
Obor 30204 Oncology
Stát vydavatele Velká Británie a Severní Irsko
Utajení není předmětem státního či obchodního tajemství
WWW URL
Impakt faktor Impact factor: 2.890
Kód RIV RIV/00216224:14110/21:00121472
Organizační jednotka Lékařská fakulta
Doi http://dx.doi.org/10.1016/j.canep.2021.101929
UT WoS 000652749700004
Klíčová slova anglicky Haematological malignancies; Subsequent primary tumour; Time trends; Standardised incidence ratio; Survival
Štítky 14110212, 14110522, 14110811, 14119612, rivok
Příznaky Mezinárodní význam, Recenzováno
Změnil Změnila: Mgr. Tereza Miškechová, učo 341652. Změněno: 15. 6. 2021 13:17.
Anotace
Background Numbers of patients who develop subsequent primary tumours have markedly increased recently. This study aimed to carry out a comprehensive analysis documenting the risk of incidence of subsequent haematological malignancies. Methods The Czech National Cancer Registry was the main data source, containing records of 126,822 haematological malignancies diagnosed in the period 1977–2016. Subsequent haematological malignancies were identified according to IACR rules. Joinpoint regression was employed to assess the time trends. The risk of development of subsequent haematological malignancy was evaluated by the standardised incidence ratio. The Kaplan–Meier curves were used to assess the differences in survival. Results Age-standardised incidence of subsequent haematological malignancies increased from 0.5 in 1977 to 9.1 in 2016. In 1992, there was a significant change in the trend: a sharp increase by 7.7 % annually was revealed thereafter. The risk of development of a haematological malignancy was approximately 1.5 times higher in persons with history of any cancer than in the general Czech population. Patients with haematological malignancies – mainly myelodysplastic syndromes, polycythaemia vera and non-Hodgkin lymphoma – were shown to be at the highest risk of developing a subsequent haematological malignancy. While the median survival following a first haematological malignancy was 2.3 years, it was only 1.1 years for subsequent haematological malignancies (p < 0.001). Conclusions Our study identified the highest-risk diagnoses in terms of development of subsequent haematological malignancy. The results might be useful to set up correctly follow-up procedures from which cancer patients could benefit.
VytisknoutZobrazeno: 24. 6. 2024 22:58